ScienceDaily
Non-small cell lung cancer patients who have progressed on a
cetuximab-containing regimen may respond to erlotinib, Fox Chase Cancer
Center researchers reported at the annual meeting of the International
Association for the Study of Lung Cancer.
Both cetuximab (Erbitux) and erlotinib (Tarceva) inhibit the epidermal
growth factor receptor (EGFR) and the assumption has been that once a
patient progresses on one EGFR inhibitor they will not respond to
another EGFR inhibitor. The new data suggests that may not be the case... Read More
Find a Doctor/Researcher
Make an Appointment
Refer a Patient
Make a Gift
Penn Cancer Network
